Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Laura Stigge

Physician Assistant, Medical Olathe, KS Physician Assistant

NPI 1326004540 CMS profile 10785426

151 W 151St St, Olathe, KS 66061

Open in the dashboard

General payments

$4,361

55 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Laura Stigge of Olathe, KS is reported in the CMS Open Payments database as having received $4,361 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $26 1
2023 General $133 1
2022 General $353 11
2021 General $3,848 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Stigge
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Laura Stigge were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Laura Stigge Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,848 $156 $41–$563 $132
2022 $353 $185 $55–$649 $149
2023 $133 $199 $58–$717 $160
2024 $26 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Amgen Inc. $2,359 13 payments
  2. Novartis Pharmaceuticals Corporation $1,284 13 payments
  3. Galderma Laboratories, L.P. $210 16 payments
  4. Genzyme Corporation $133 1 payment
  5. LEO Pharma Inc. $81 2 payments
  6. Regeneron Healthcare Solutions, Inc. $74 1 payment
  7. UCB, Inc. $74 1 payment
  8. Janssen Biotech, Inc. $70 1 payment
  9. Genentech USA, Inc. $49 6 payments
  10. Arcutis Biotherapeutics, Inc. $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,250 4 payments
  2. Food and Beverage $1,026 49 payments
  3. Consulting Fee $1,015 1 payment
  4. Education $70 1 payment
Products named General payments · program years 2021–2024
  1. Otezla $2,359 13 payments
  2. COSENTYX $1,284 13 payments
  3. ORACEA $93 9 payments
  4. AKLIEF $93 9 payments
  5. ADBRY $81 2 payments
  6. EPIDUO FORTE $80 7 payments
  7. DUPIXENT $74 1 payment
  8. Cimzia $74 1 payment
  9. TREMFYA $70 1 payment
  10. Erivedge $49 6 payments
  11. Other $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record